http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2770745-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04b8a678ba7abebe98b1db12e673dd4b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 |
| filingDate | 2021-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d34e35e8870bfa49c5a06ab16efcfb32 |
| publicationDate | 2022-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2770745-C1 |
| titleOfInvention | Combined method for treating choroidal neovasculation of all types |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to ophthalmology. Intravitreal introduction of angiogenesis inhibitors and laser coagulation of choroidal neovascularization (CNV) foci are performed. If active CNV foci are identified after intravitreal injections of the angiogenesis inhibitor, laser coagulation of the CNV focus is performed from the outer edge of the focus to the centre. Laser radiation with a wavelength of 532 nm, a power of 200 to 350 m W, a pulse duration of 0.05 to 0.07 s, a period between pulses of 0.2 to 0.3 s, a spot diameter of the laser applicator of 300 mcm is therein used, with an amount of laser applicators of 150 to 1,300 pcs, wherein each subsequent coagulate is adjacent to the previous one. The first pass of the laser is therein started applying laser coagulants on the II degree on the L'Esperance scale, the focus is subjected to triple coagulation with a gradual increase of the laser radiation energy by a quarter from the initial parameters. In a particular case, if the activity of CNV is maintained, additional intravitreal injections of the angiogenesis inhibitor are performed. n EFFECT: method allows for reliable and safe limitation and even complete termination of the process of pathological choroidal angiogenesis, with a lasting effect. n 2 cl, 10 ex, 23 dwg |
| priorityDate | 2021-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.